Sarepta Therapeutics, Inc. (SRPT) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Sarepta Therapeutics, Inc. (SRPT) Bundle
Streamline your analysis and improve precision with our [SRPT] DCF Calculator! With up-to-date Sarepta Therapeutics data and customizable assumptions, this tool empowers you to forecast, evaluate, and value Sarepta Therapeutics like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 380.8 | 540.1 | 701.9 | 933.0 | 1,243.3 | 1,672.2 | 2,248.9 | 3,024.6 | 4,067.9 | 5,470.9 |
| Revenue Growth, % | 0 | 41.82 | 29.96 | 32.93 | 33.26 | 34.49 | 34.49 | 34.49 | 34.49 | 34.49 |
| EBITDA | -652.7 | -453.4 | -306.1 | -582.1 | -439.2 | -1,087.8 | -1,463.0 | -1,967.6 | -2,646.3 | -3,559.0 |
| EBITDA, % | -171.38 | -83.94 | -43.61 | -62.39 | -35.32 | -65.05 | -65.05 | -65.05 | -65.05 | -65.05 |
| Depreciation | 30.5 | 39.7 | 49.3 | 54.6 | 58.9 | 110.4 | 148.4 | 199.6 | 268.5 | 361.0 |
| Depreciation, % | 8.02 | 7.36 | 7.03 | 5.85 | 4.74 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 |
| EBIT | -683.2 | -493.1 | -355.4 | -636.7 | -498.1 | -1,171.3 | -1,575.3 | -2,118.7 | -2,849.5 | -3,832.3 |
| EBIT, % | -179.4 | -91.3 | -50.64 | -68.24 | -40.06 | -70.05 | -70.05 | -70.05 | -70.05 | -70.05 |
| Total Cash | 1,124.7 | 1,938.6 | 2,115.9 | 1,989.4 | 1,676.3 | 1,672.2 | 2,248.9 | 3,024.6 | 4,067.9 | 5,470.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 90.9 | 135.5 | 171.6 | 259.7 | 439.7 | 456.9 | 614.4 | 826.4 | 1,111.4 | 1,494.7 |
| Account Receivables, % | 23.86 | 25.09 | 24.45 | 27.83 | 35.37 | 27.32 | 27.32 | 27.32 | 27.32 | 27.32 |
| Inventories | 171.4 | 232.0 | 186.2 | 204.0 | 322.9 | 542.8 | 730.0 | 981.8 | 1,320.5 | 1,775.9 |
| Inventories, % | 45 | 42.95 | 26.53 | 21.86 | 25.97 | 32.46 | 32.46 | 32.46 | 32.46 | 32.46 |
| Accounts Payable | 68.1 | 111.1 | 76.7 | 95.9 | 164.9 | 243.9 | 328.0 | 441.1 | 593.3 | 797.9 |
| Accounts Payable, % | 17.88 | 20.57 | 10.93 | 10.28 | 13.26 | 14.58 | 14.58 | 14.58 | 14.58 | 14.58 |
| Capital Expenditure | -62.7 | -82.2 | -38.5 | -30.8 | -76.1 | -155.8 | -209.6 | -281.9 | -379.1 | -509.8 |
| Capital Expenditure, % | -16.47 | -15.22 | -5.48 | -3.3 | -6.12 | -9.32 | -9.32 | -9.32 | -9.32 | -9.32 |
| Tax Rate, % | -3.05 | -3.05 | -3.05 | -3.05 | -3.05 | -3.05 | -3.05 | -3.05 | -3.05 | -3.05 |
| EBITAT | -684.4 | -494.1 | -355.3 | -649.2 | -513.3 | -1,171.2 | -1,575.2 | -2,118.5 | -2,849.2 | -3,832.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -910.7 | -598.8 | -369.1 | -712.1 | -760.4 | -1,374.9 | -1,897.1 | -2,551.4 | -3,431.4 | -4,614.9 |
| WACC, % | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -10,648.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -4,707 | |||||||||
| Terminal Value | -80,870 | |||||||||
| Present Terminal Value | -55,498 | |||||||||
| Enterprise Value | -66,147 | |||||||||
| Net Debt | 968 | |||||||||
| Equity Value | -67,115 | |||||||||
| Diluted Shares Outstanding, MM | 92 | |||||||||
| Equity Value Per Share | -726.37 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled real SRPT financial data.
- Authentic Data: Access to historical figures and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust forecast parameters such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs influence Sarepta’s valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Design: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Comprehensive Clinical Data: Access detailed pre-loaded historical clinical trial results and future pipeline projections for Sarepta Therapeutics, Inc. (SRPT).
- Customizable Assumptions: Modify highlighted fields such as R&D expenses, market penetration rates, and pricing strategies.
- Real-Time Analytics: Automatic updates to valuation metrics, including Discounted Cash Flow (DCF) and Net Present Value (NPV).
- Interactive Dashboard: User-friendly charts and summaries to effectively visualize your investment analysis.
- Designed for All Users: An intuitive interface suitable for both seasoned investors and newcomers in the biotech sector.
How It Works
- Step 1: Download the prebuilt Excel template featuring Sarepta Therapeutics, Inc.'s (SRPT) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including Sarepta's intrinsic value.
- Step 5: Make informed investment choices or create reports based on the outputs.
Why Choose Sarepta Therapeutics, Inc. (SRPT)?
- Innovative Solutions: Cutting-edge therapies designed to address rare genetic diseases.
- Proven Expertise: A dedicated team of professionals with extensive experience in biotechnology.
- Commitment to Patients: Focused on improving the lives of individuals with serious medical conditions.
- Robust Pipeline: A diverse range of products in various stages of development.
- Industry Recognition: Acknowledged for leadership in gene therapy and muscular dystrophy treatments.
Who Should Use This Product?
- Investors: Evaluate Sarepta Therapeutics' (SRPT) market potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess future forecasts.
- Biotech Entrepreneurs: Understand how leading biotech firms like Sarepta Therapeutics are appraised.
- Consultants: Create comprehensive valuation reports for clients in the biotech sector.
- Students and Educators: Utilize real-world biotech data to learn and teach valuation principles.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Sarepta Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Sarepta Therapeutics.
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.